Analysts Set Alto Neuroscience, Inc. (NYSE:ANRO) PT at $15.40

Alto Neuroscience, Inc. (NYSE:ANRO - Get Free Report) has received a consensus rating of "Moderate Buy" from the seven research firms that are presently covering the stock, Marketbeat Ratings reports. Three analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The average 1-year price target among brokers that have issued ratings on the stock in the last year is $15.40.

ANRO has been the topic of a number of recent analyst reports. HC Wainwright assumed coverage on shares of Alto Neuroscience in a research note on Monday, April 7th. They set a "buy" rating and a $10.00 price target on the stock. William Blair reaffirmed an "outperform" rating on shares of Alto Neuroscience in a research report on Friday, March 21st.

Institutional Trading of Alto Neuroscience

Large investors have recently added to or reduced their stakes in the stock. Marshall Wace LLP acquired a new position in Alto Neuroscience during the 4th quarter worth approximately $3,542,000. Point72 Asset Management L.P. raised its stake in shares of Alto Neuroscience by 73.1% during the fourth quarter. Point72 Asset Management L.P. now owns 1,692,153 shares of the company's stock valued at $7,158,000 after purchasing an additional 714,461 shares during the period. Franklin Resources Inc. lifted its position in shares of Alto Neuroscience by 95.3% during the third quarter. Franklin Resources Inc. now owns 1,220,712 shares of the company's stock worth $13,965,000 after purchasing an additional 595,673 shares in the last quarter. Woodline Partners LP boosted its stake in shares of Alto Neuroscience by 397.6% in the fourth quarter. Woodline Partners LP now owns 621,976 shares of the company's stock valued at $2,631,000 after purchasing an additional 496,976 shares during the period. Finally, Northern Trust Corp grew its holdings in Alto Neuroscience by 198.1% during the 4th quarter. Northern Trust Corp now owns 587,135 shares of the company's stock valued at $2,484,000 after purchasing an additional 390,190 shares in the last quarter.

Alto Neuroscience Trading Down 0.2 %

Shares of ANRO stock traded down $0.01 during mid-day trading on Tuesday, hitting $2.25. 148,826 shares of the company's stock were exchanged, compared to its average volume of 376,600. The stock has a market cap of $60.78 million, a price-to-earnings ratio of -0.88 and a beta of 2.16. The company has a quick ratio of 13.09, a current ratio of 13.10 and a debt-to-equity ratio of 0.05. Alto Neuroscience has a fifty-two week low of $1.60 and a fifty-two week high of $17.55. The stock has a 50-day simple moving average of $2.73 and a two-hundred day simple moving average of $4.49.

Alto Neuroscience (NYSE:ANRO - Get Free Report) last issued its quarterly earnings results on Thursday, March 20th. The company reported ($0.56) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.65) by $0.09. Equities analysts expect that Alto Neuroscience will post -2.54 EPS for the current fiscal year.

Alto Neuroscience Company Profile

Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.